Introduction:
The unrelenting storm of coronavirus disease (COVID-19), which has
emerged since December 2019, has turned into a crucial health matter of
the globe. This infection has involved over 90 million people worldwide
and led to death in approximately 2 million cases. This pandemic’s exact
pathophysiology is unknown yet, and scientists are searching for
efficient management approaches to this infection(1, 2).
COVID-19 is an acute complex systemic disorder which presentation varies
from mild influenza-like symptoms to catastrophic conditions by
interstitial pneumonia progressing to acute respiratory distress
syndrome (ARDS), sepsis, and multi-organ failure(3).
Increasing evidence is going on regarding hypercoagulable states among
those infected with COVID-19, also known as severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). The epidemiological studies have
stated a wide range of 7.7-49% for thrombotic events incidence in
COVID-19 infected patients, including deep vein thrombosis (DVT),
pulmonary thromboembolism (PTE), ischemic cerebrovascular accident
(CVA), acute myocardial infarction (AMI), and arterial thrombosis (4-7).
An increase in the inflammatory factors, endothelial dysfunction, and
thromboinflammation propagated by angiotensin-converting enzyme-2 are
the potential factors presumed to play a role in coagulopathy
pathogenesis (8).
Although numerous studies have been conducted to assess the prevalence,
etiology, and features of thromboembolic events due to SARS-CoV-2, the
knowledge in this regard is limited(9, 10). Therefore, the current study
aims to clarify the correlation between thromboembolic events incidence
in COVID-19 and the patient, infection, and in-hospital related
characteristics.